Maveropepimut-s is under clinical development by IMV and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Maveropepimut-s’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Maveropepimut-s overview

Maveropepimut-s (DPX-Survivac) is under development for the treatment of glioblastoma, ovarian cancer, fallopian tube cancer, bladder cancer, liver cancer (hepatocellular carcinoma), non-small cell lung (NSCLC) cancer as well as tumors shown to be positive for the microsatellite instability-high (MSI-H) biomarker, diffuse large B-cell lymphoma, peritoneal cancer and (HR+/HER2-) breast cancer. It is administered subcutaneously. It comprises survivin-based antigens formulated in the DepoVax delivery platform and DPX platform. It was also under development for the treatment of prostate cancer.

See Also:

IMV overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

IMV, formerly Immunovaccine Inc, is a biopharmaceutical company that develops immunotherapies and vaccines to treat cancer and infectious diseases. The company is investigating its pipeline candidates DPX-Survivac against ovarian, bladder, liver, non-small cell lung cancer and diffuse large B cell lymphoma (DLBCL); DPX-RSV for Respiratory Syncytial Virus (RSV); and DPX-Covid-19 for the treatment of coronavirus. It is also advancing DPX-SurMAGE against bladder cancer and DPX-BRAF to treat melanoma. IMV harnesses its proprietary DPX platform technology to deliver drugs. The company partners with pharmaceutical companies, academic research institutions and government agencies to research and develop therapies for cancer. IMV is headquartered in Dartmouth, Nova Scotia, Canada.

For a complete picture of Maveropepimut-s’s drug-specific PTSR and LoA scores, buy the report here.